Comments
Drugmaker Cipla has entered into a commercial collaboration with BioQuiddity Inc for BioQuiddity’s OneDose ReadyfusOR anaesthetic applications for post-surgical pain management. The agreement covers the European Union and other countries in the region, Cipla said.
Cipla intends to launch this product pre-filled with anaesthetic drug Ropivacaine under its own label in the German market later this year.
The deal is being executed through Cipla Europe NV, a wholly-owned subsidiary of Mumbai-based Cipla Ltd. San Francisco-based BioQuiddity is a privately held corporation focused on unmet needs in drug infusion today — cost, medication error, sterility, efficiency, and patient quality of life, the note said.
“Cipla is an excellent strategic partner for BioQuiddity and our pre-filled ready-to-use post-surgical pain product candidates,” Joshua Kriesel, President and Chief Executive, said in a statement. “Cipla’s strong commercial record puts them in an outstanding position to detail the OneDose ReadyfusOR’s safety, sterility, and ease-of-use value proposition objectives,” he added.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.